MX2020008415A - Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. - Google Patents

Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.

Info

Publication number
MX2020008415A
MX2020008415A MX2020008415A MX2020008415A MX2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treg cells
act selectively
treg lymphocytes
Prior art date
Application number
MX2020008415A
Other languages
English (en)
Inventor
Philip M Arlen
Kwong Y Tsang
Justin M David
Massimo Fantini
Original Assignee
Prec Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biologics Inc filed Critical Prec Biologics Inc
Publication of MX2020008415A publication Critical patent/MX2020008415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se muestra que el anticuerpo NEO-201 se une a los linfocitos Treg, y se describe su use para seleccionar linfocitos Treg como diana. NEO-201 puede usarse para aislar, detectar o purificar linfocitos Treg activos y tambien para destruir linfocitos Treg. Se describen los metodos terapeuticos y las politerapias que usan NEO-201 opcionalmente en combinaci6n con otro agente.
MX2020008415A 2018-02-13 2019-02-13 Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. MX2020008415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630084P 2018-02-13 2018-02-13
PCT/US2019/017870 WO2019160970A1 (en) 2018-02-13 2019-02-13 Methods and compositions for targeting treg cells

Publications (1)

Publication Number Publication Date
MX2020008415A true MX2020008415A (es) 2020-10-28

Family

ID=67619085

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008415A MX2020008415A (es) 2018-02-13 2019-02-13 Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.
MX2025010847A MX2025010847A (es) 2018-02-13 2020-08-11 Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025010847A MX2025010847A (es) 2018-02-13 2020-08-11 Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg

Country Status (9)

Country Link
US (2) US12037410B2 (es)
EP (1) EP3752533A4 (es)
JP (2) JP7555270B2 (es)
CN (1) CN112041343B (es)
AU (2) AU2019221544B2 (es)
BR (1) BR112020016374A2 (es)
CA (1) CA3091181A1 (es)
MX (2) MX2020008415A (es)
WO (1) WO2019160970A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013637A (es) * 2021-05-19 2024-02-13 Prec Biologics Inc Metodos y composiciones para tratar neoplasias hematicas.
CN114010803B (zh) * 2021-11-30 2023-04-07 广东省人民医院 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用
EP4499710A4 (en) * 2022-05-19 2026-04-15 Prec Biologics Inc METHODS FOR ABLATION OF SUPPRESSIVE MYELOID CELLS USING A NEO-201 ANTIBODY

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010A (en) 1841-03-18 Machine foe
US4810781A (en) 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
USRE39760E1 (en) 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5688657A (en) 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP1320551A4 (en) 2000-09-01 2006-12-20 Internat Bioimmune Systems Inc IDENTIFICATION AND DEVELOPMENT OF SPECIFIC MONOCLONAL ANTIBODIES AGAINST SQUAFTEPITHELIC CARCINOMA
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
WO2009062050A2 (en) 2007-11-08 2009-05-14 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US8277804B2 (en) * 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2010105298A1 (en) 2009-03-18 2010-09-23 Simon Barry Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof
WO2011139738A2 (en) * 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
WO2012075111A1 (en) * 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
JP2013059295A (ja) * 2011-09-14 2013-04-04 Nagoya City Univ ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
EP3043819A4 (en) * 2013-09-11 2017-04-05 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
JP6815329B2 (ja) * 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ｃｅａｃａｍ６抗体およびその使用
US11279768B1 (en) * 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
EP3295171A1 (en) * 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
PL3440109T3 (pl) * 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
US11020467B2 (en) * 2017-05-26 2021-06-01 Etubics Corporation Combination immunotherapies comprising IL-15 superagonists
CN120860200A (zh) 2017-11-03 2025-10-31 精密生物制品股份有限公司 用于治疗人癌瘤的单克隆抗体neo-201
WO2020018425A1 (en) * 2018-07-16 2020-01-23 Nantcell, Inc. Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201

Also Published As

Publication number Publication date
WO2019160970A1 (en) 2019-08-22
MX2025010847A (es) 2025-10-01
EP3752533A1 (en) 2020-12-23
JP2021512965A (ja) 2021-05-20
AU2019221544B2 (en) 2025-07-10
JP7874689B2 (ja) 2026-06-16
JP7555270B2 (ja) 2024-09-24
CA3091181A1 (en) 2019-08-22
CN112041343B (zh) 2024-08-30
US20240400714A1 (en) 2024-12-05
BR112020016374A2 (pt) 2020-12-15
AU2019221544A1 (en) 2020-10-01
CN112041343A (zh) 2020-12-04
JP2024177188A (ja) 2024-12-19
US12037410B2 (en) 2024-07-16
US20210002383A1 (en) 2021-01-07
EP3752533A4 (en) 2021-05-05
AU2025248631A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2018003353A (es) Terapias con celulas cart con una eficacia mejorada.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
PH12019501010A1 (en) Arginase inhibitor combination therapies
CL2021001432A1 (es) Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
MX2020005477A (es) Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MX2017007537A (es) Anticuerpos anti-pd-1 y sus metodos de uso.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112015013123A2 (pt) inibidores de beta-lactamase
MX381718B (es) Agentes biologicos y su uso en plantas.
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2017013613A (es) Neoepitodos de cancer.
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
MX2025010847A (es) Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos